🇺🇸 FDA
Pipeline program

A study in healthy men to test whether zongertinib influences the amount of 4 other medicines (dabigatran, rosuvastatin, metformin, and furosemide) in the blood

1479-0015

Phase 1 other active

Quick answer

A study in healthy men to test whether zongertinib influences the amount of 4 other medicines (dabigatran, rosuvastatin, metformin, and furosemide) in the blood for Pharmacokinetic trial is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Pharmacokinetic trial
Phase
Phase 1
Modality
other
Status
active

Clinical trials